{"id":"https://openalex.org/W3097628887","doi":"https://doi.org/10.1182/blood-2020-139910","title":"Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial","display_name":"Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097628887","doi":"https://doi.org/10.1182/blood-2020-139910","mag":"3097628887"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-139910","doi":"https://doi.org/10.1182/blood-2020-139910","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139910","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038597185","display_name":"Amy D. Shapiro","orcid":"https://orcid.org/0000-0003-2821-7159","observed_orcids":["https://orcid.org/0000-0003-2821-7159"]},"institutions":[{"id":"https://openalex.org/I4210162902","display_name":"Indiana Hemophilia and Thrombosis Center","ror":"https://ror.org/05j1fg548","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210162902"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy D Shapiro","raw_affiliation_strings":["Indiana Hemophilia & Thrombosis Center, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana Hemophilia & Thrombosis Center, Indianapolis, IN","institution_ids":["https://openalex.org/I4210162902"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006881585","display_name":"Giancarlo Castaman","orcid":"https://orcid.org/0000-0003-4973-1317","observed_orcids":["https://orcid.org/0000-0003-4973-1317"]},"institutions":[{"id":"https://openalex.org/I4210115393","display_name":"Azienda Ospedaliero-Universitaria Careggi","ror":"https://ror.org/02crev113","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210115393"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giancarlo Castaman","raw_affiliation_strings":["Azienda Ospedaliera Universitaria Careggi, Florence, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Azienda Ospedaliera Universitaria Careggi, Florence, Italy","institution_ids":["https://openalex.org/I4210115393"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065668226","display_name":"Katarina Cepo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Katarina Cepo","raw_affiliation_strings":["Biopharm Medical & Science, Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biopharm Medical & Science, Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002537345","display_name":"Sidsel Marie T\u00f8nder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Sidsel Marie T\u00f8nder","raw_affiliation_strings":["Biostatistics Biopharm 1, Novo Nordisk A/S, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics Biopharm 1, Novo Nordisk A/S, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047434427","display_name":"Tadashi Matsushita","orcid":"https://orcid.org/0000-0002-3646-3125","observed_orcids":["https://orcid.org/0000-0002-3646-3125"]},"institutions":[{"id":"https://openalex.org/I4210090647","display_name":"Nagoya University Hospital","ror":"https://ror.org/008zz8m46","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210090647"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tadashi Matsushita","raw_affiliation_strings":["Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan","institution_ids":["https://openalex.org/I4210090647"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108531876","display_name":"Lone Hvitfeldt Poulsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204337017","display_name":"Aarhus University","ror":"https://ror.org/01aj84f44","country_code":"DK","type":"education","lineage":["https://openalex.org/I204337017"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Lone Hvitfeldt Poulsen","raw_affiliation_strings":["The Haemophilia Centre, Department of Haematology, Aarhus University, Aarhus, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Haemophilia Centre, Department of Haematology, Aarhus University, Aarhus, Denmark","institution_ids":["https://openalex.org/I204337017"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004338432","display_name":"Guy A. Young","orcid":"https://orcid.org/0000-0001-6013-1254","observed_orcids":["https://orcid.org/0000-0001-6013-1254"]},"institutions":[{"id":"https://openalex.org/I1174212","display_name":"University of Southern California","ror":"https://ror.org/03taz7m60","country_code":"US","type":"education","lineage":["https://openalex.org/I1174212"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guy Young","raw_affiliation_strings":["Keck School of Medicine, University of Southern California, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Keck School of Medicine, University of Southern California, Los Angeles, CA","institution_ids":["https://openalex.org/I1174212"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082757602","display_name":"Silva Zupan\u010di\u0107\u2010\u0160alek","orcid":"https://orcid.org/0000-0002-6244-2336","observed_orcids":["https://orcid.org/0000-0002-6244-2336"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Silva Zupancic-\u0160alek","raw_affiliation_strings":["Department of Hemostasis, Thrombosis and Non-Aligned Hematology, Hematology Institute Zagreb, Zagreb, Croatia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hemostasis, Thrombosis and Non-Aligned Hematology, Hematology Institute Zagreb, Zagreb, Croatia","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050723834","display_name":"V\u00edctor Jim\u00e9nez\u2010Yuste","orcid":"https://orcid.org/0000-0003-3937-3499","observed_orcids":["https://orcid.org/0000-0003-3937-3499"]},"institutions":[{"id":"https://openalex.org/I2800562746","display_name":"Hospital Universitario La Paz","ror":"https://ror.org/01s1q0w69","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800562746"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Victor Jimenez Yuste","raw_affiliation_strings":["Haematology Department, La Paz University Hospital, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Haematology Department, La Paz University Hospital, Madrid, Spain","institution_ids":["https://openalex.org/I2800562746"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.3333,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.6031502,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"40","last_page":"41"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/concizumab","display_name":"concizumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/tissue-factor-pathway-inhibitor","display_name":"tissue factor pathway inhibitor","score":0.8429999947547913},{"id":"https://openalex.org/keywords/prophylaxis","display_name":"prophylaxis","score":0.734000027179718},{"id":"https://openalex.org/keywords/annualized-bleeding-rate","display_name":"annualized bleeding rate","score":0.8899999856948853},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7519999742507935},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6800000071525574},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.6029999852180481},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5460000038146973},{"id":"https://openalex.org/keywords/recombinant-factor-viia","display_name":"recombinant factor VIIa","score":0.7789999842643738},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5659999847412109},{"id":"https://openalex.org/keywords/bleeding-prevention","display_name":"bleeding prevention","score":0.5299999713897705},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.574999988079071},{"id":"https://openalex.org/keywords/coagulation-factor-replacement-therapy","display_name":"factor replacement therapy","score":0.4399999976158142},{"id":"https://openalex.org/keywords/factor-ix","display_name":"factor IX","score":0.9750000238418579}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8894891738891602},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5558868646621704},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5459089279174805},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.5198057889938354},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4999065399169922},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48253223299980164},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37457531690597534}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-139910","doi":"https://doi.org/10.1182/blood-2020-139910","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-139910","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2982788002","https://openalex.org/W7118731927","https://openalex.org/W4310159127","https://openalex.org/W2986183021","https://openalex.org/W4389247922","https://openalex.org/W4386272373","https://openalex.org/W4417019469","https://openalex.org/W4221100730","https://openalex.org/W7160832886","https://openalex.org/W7165734041"],"abstract_inverted_index":{"Introduction":[0],"Concizumab":[1,206],"is":[2],"a":[3,75,223,306],"high-affinity,":[4],"anti-tissue":[5],"factor":[6,180],"pathway":[7],"inhibitor":[8],"(TFPI)":[9],"monoclonal":[10],"antibody":[11],"currently":[12],"in":[13,58,113,116,141,191,215,317,366,446,488,500,522,531,559],"clinical":[14,526],"investigation":[15],"for":[16,84,202,378,554],"the":[17,30,41,51,101,109,127,145,149,159,163,184,187,192,203,217,239,244,248,334,354,358,367,374,385,397,408,433,437,478,484,509,516,525,532,536,543],"once-daily":[18],"subcutaneous":[19,549],"prophylactic":[20,550],"treatment":[21,176,350,551],"of":[22,40,56,100,104,111,144,148,162,186,243,247,257,267,283,289,296,312,345,357,428,436,459,483,515,528,535,542,548,579,598,614,636,651,667,679,710,871],"patients":[23,59,117,165,190,326,347,380,415,447,454,502,560],"with":[24,60,63,69,118,177,310,327,338,342,351,382,504,524,552,561],"hemophilia.":[25],"We":[26],"present":[27],"results":[28],"from":[29,508],"combined":[31,510],"main":[32,76,102,146,160,188,218,318,355,386,409,479,511,533],"and":[33,53,66,87,212,219,234,254,270,287,319,340,387,410,474,480,495,512,538,545,563,814,819],"extension":[34,89,204,220,245,320,368,388,411,434,481,513],"parts":[35,221,389,482,514],"(at":[36],"least":[37,81,94,133,264,556],"76":[38,265,280,294,557],"weeks)":[39],"phase":[42,517],"2":[43,518],"explorer4":[44,73,105,335,519],"trial":[45,150,249,359,398,438,520,537],"(NCT03196284),":[46],"which":[47,78,91],"aimed":[48],"to":[49,107,169,198,210,251,275,315,331,469],"assess":[50,108,252],"safety":[52,253,544],"longer-term":[54,255,546],"efficacy":[55,110,256,547],"concizumab":[57,112,172,201,269,316,332,364,383,429,442,450,553],"hemophilia":[61,67],"A":[62],"inhibitors":[64,70,328],"(HAwI)":[65],"B":[68],"(HBwI).":[71],"Methods":[72],"comprised":[74],"part,":[77,90,189],"lasted":[79,92],"at":[80,93,126,132,263,279,373,555],"24":[82,134],"weeks":[83,233,266,295,558],"all":[85,379],"patients,":[86],"an":[88,576,595,611,633,648,664,676,707,868],"52":[95],"weeks.":[96,135],"The":[97,241,370],"primary":[98],"objective":[99,137,242],"part":[103,147,161,246,321,356,435,534],"was":[106,208,250,299,390,400,444],"preventing":[114],"bleeds":[115],"HAwI/HBwI,":[119],"evaluated":[120],"as":[121,322],"annualized":[122],"bleeding":[123,229,419],"rate":[124],"(ABR)":[125],"last":[128,276,375,423],"dose":[129,207,277,365,376,424],"level":[130,377],"after":[131,262],"This":[136],"has":[138],"been":[139],"addressed":[140],"previous":[142],"reporting":[143],"(Shapiro":[151],"A,":[152],"et":[153],"al.":[154],"Blood":[155,687],"2019;":[156],"134[22]:1973-1982).":[157],"During":[158,407],"trial,":[164],"were":[166,196,329,430,465,498,521],"randomized":[167],"2:1":[168],"receive":[170],"either":[171],"prophylaxis":[173],"or":[174,581,600,616,638,653,669,681,712,873],"on-demand":[175,194,349],"recombinant":[178],"activated":[179],"VII":[181],"(rFVIIa).":[182],"At":[183],"end":[185],"rFVIIa":[193,352],"arm":[195],"switched":[197],"0.15":[199],"mg/kg":[200,214],"part.":[205],"escalated":[209],"0.20":[211,451],"0.25":[213],"both":[216],"if":[222,235],"patient":[224],"experienced":[225],"\u22653":[226],"treated":[227,381,418,503],"spontaneous":[228],"episodes":[230,420],"within":[231],"12":[232],"deemed":[236],"safe":[237],"by":[238],"investigator.":[240],"concizumab.":[258,505],"Endpoints":[259],"included":[260],"ABR":[261,298,372],"treatment,":[268],"free":[271,460],"TFPI":[272,461],"concentrations":[273,427,458],"prior":[274],"administration":[278],"weeks,":[281],"number":[282],"adverse":[284],"events":[285,473],"(AEs)":[286],"occurrence":[288],"anti-drug":[290],"antibodies":[291],"(ADAs)":[292],"during":[293,333,353,384,396,432,477],"treatment.":[297],"estimated":[300,371],"using":[301],"LS-means":[302],"estimates,":[303],"based":[304],"on":[305,421,575,594,610,632,647,663,675,706,867],"negative":[307],"binomial":[308],"regression":[309],"log":[311],"exposure":[313],"time":[314],"offset.":[323],"Results":[324,507],"Twenty-five":[325],"exposed":[330],"trial;":[336],"15":[337],"HAwI":[339,562],"10":[341],"HBwI.":[343,564],"Eight":[344],"these":[346,453],"received":[348,449],"before":[360],"receiving":[361],"their":[362,422],"first":[363],"phase.":[369],"4.8":[391],"(95%":[392,402],"CI:":[393,403],"3.2-7.2),":[394],"while":[395],"this":[399],"5.7":[401],"4.2\u22127.8)":[404],"(Table":[405,439,462],"1).":[406],"parts,":[412],"4":[413],"(16%)":[414],"had":[416,456],"zero":[417],"level.":[425],"Plasma":[426],"variable":[431],"2).":[440,463],"Increased":[441],"concentration":[443],"observed":[445,499],"who":[448],"mg/kg;":[452],"also":[455],"lower":[457],"There":[464],"no":[466,471,475],"AEs":[467],"leading":[468],"withdrawal,":[470],"thromboembolic":[472],"deaths":[476],"trial.":[485],"ADAs":[486],"developed":[487],"6":[489],"patients.":[490],"Elevated":[491],"prothrombin":[492],"fragment":[493],"1+2":[494],"D-dimer":[496],"levels":[497],"some":[501],"Conclusions":[506],"line":[523],"proof":[527],"concept":[529],"established":[530],"provided":[539],"further":[540],"details":[541],"Disclosures":[565],"Shapiro:":[566],"BioMarin:":[567],"Research":[568,571,584,589,603,620,623,627,643,656,684,689,692,695,701,718,722,734,773,777,781,821,858,876,881,885,892],"Funding;":[569,572,590,621,624,628,644,657,685,690,693,696,719,723,774,778,782,859,877,882,886,893],"Agios:":[570],"Genentech/Roche:":[573],"Membership":[574,593,609,631,646,662,674,705,866],"entity's":[577,596,612,634,649,665,677,708,869],"Board":[578,597,613,635,650,666,678,709,870],"Directors":[580,599,615,637,652,668,680,711,872],"advisory":[582,601,617,639,654,670,682,713,874],"committees,":[583,602,655,683,875],"Funding,":[585,604,735],"Speakers":[586,605,736,741,744,747,752,828,832,836,840,844,848,852],"Bureau;":[587,606,737,742,745,748,829,833,837,841,845,849],"Novartis:":[588],"Novo":[591,658,738,770,808],"Nordisk:":[592,739,755,760,771],"Catalyst":[607],"BioSciences:":[608],"committees;":[618,640,671,714],"Sangamo:":[619],"OPKO:":[622],"Daiichi":[625],"Sankyo:":[626],"Sigilon:":[629],"Consultancy,":[630,673,700,750,768,856,861,864,879,890],"Kedrion":[641],"Biopharma:":[642],"Takeda:":[645,820,834,863],"Nordisk":[659],"Hemophilia":[660],"Foundation:":[661],"Bioverativ:":[672],"Glover":[686],"Therapeutics:":[688,699],"Octapharma:":[691,838,896],"Pfizer:":[694,720,779,878],"ProMetic":[697],"Bio":[698],"Funding.":[702,822],"Castaman:Uniqure:":[703],"Honoraria,":[704,717,721,733,740,751,772,776,780,827,831,835,839,843,847,851,857,865,880,884,891],"CSL":[715,798],"Behring:":[716],"Ablynx:":[724],"Honoraria;":[725,727,729,731,764,766,769,784,786,788,790,792,794,816,862,888,895],"Alexion:":[726],"Bayer:":[728,767,850,887],"Baxalta/Shire:":[730],"Sobi:":[732,846,889],"Werfen:":[743],"Kedrion:":[746],"Roche:":[749,842,860],"Bureau.":[753,853],"Cepo:Novo":[754],"Current":[756,761],"Employment.":[757,762],"Marie":[758],"T\u00f8nder:Novo":[759],"Matsushita:Sysmex:":[763],"Octapharm:":[765],"Chugai:":[775],"Shire/Takeda:":[783],"Bioverative/Sanofi:":[785],"CSL:":[787,894],"JB:":[789],"KMB:":[791],"Kirin:":[793],"Nichiyaku:":[795],"Honoraria.":[796,897],"Young:Bayer,":[797],"Behring,":[799],"Freeline,":[800,804],"UniQure:":[801,815],"Consultancy;":[802],"BioMarin,":[803],"Genentech/Roche,":[805,817],"Grifols,":[806,818],"Kedrion,":[807],"Nordisk,":[809],"Sanofi":[810],"Genzyme,":[811],"Spark,":[812],"Takeda,":[813],"Zupancic-\u0160alek:NovoNordisk":[823],"Health":[824],"Care":[825],"AG:":[826],"Baxter:":[830],"Jimenez":[854],"Yuste:NovoNordisk:":[855],"Grifols:":[883]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}